FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - December 5, 2025 252 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Genomic and Immunophenotypic Heterogeneity of Acquired Resistance to Immune Checkpoint Inhibitors... January 30, 2024 Woman Donates 500 Care Packages To Breast Cancer Patients October 11, 2021 What to Say to Someone With Cancer: A Patient Perspective July 14, 2022 FDA Approves Blinatumomab as Consolidation for CD19-positive Philadelphia Chromosome-negative B-Cell Precursor... August 6, 2024 Load more HOT NEWS Following Abnormal Cancer Screening Results, Multi-Level Reminders May Increase Follow-Up Healthy and Delicious Figs Severe Immune-Related Gastroenterocolitis Described After in Utero Exposure to Pembrolizumab Qué debo saber sobre la mastectomía con cierre plano después de...
